Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Applied DNA Sciences, Inc. (APDN) delivers innovative synthetic DNA solutions for therapeutic development, molecular diagnostics, and supply chain security. This news hub provides investors and industry professionals with centralized access to official corporate announcements and verified updates.
Track critical developments across the company's core operations, including advancements in PCR-based DNA production, diagnostic testing services, and anti-counterfeiting technologies. Our curated feed features earnings reports, strategic partnerships, product launches, and regulatory milestones that impact APDN's market position.
Key focus areas include updates on the Linea DNA platform for mRNA therapeutics, CertainT forensic authentication solutions, and clinical testing services. Users benefit from timestamped press releases organized chronologically while maintaining factual accuracy and regulatory compliance.
Bookmark this page for direct access to Applied DNA Sciences' latest financial disclosures, technology patents, and supply chain security initiatives. Check regularly for updates on nucleic acid manufacturing innovations and DNA-based brand protection programs shaping the biotechnology sector.
Applied DNA Sciences (NASDAQ: APDN) reported a record revenue of $6.1 million for Q2 FY2022, marking a 130% year-over-year increase and 48% sequential growth. The company has cash reserves of $6.5 million post a registered direct offering. Demand for COVID-19 testing remains strong, driven by academic and corporate clients. The company is advancing its LinearDNA platform and expects to commercialize RNA-based therapeutics. Despite a net loss of $1.8 million, the outlook for continued revenue growth remains positive.
Applied DNA Sciences (NASDAQ: APDN) will report its fiscal 2022 second quarter financial results on May 12, 2022, after market close. The management team will host a conference call at 4:30 p.m. ET to discuss the results, which will also be available via webcast. Applied DNA specializes in enzymatic DNA production, particularly through its LinearDNA platform, which supports various applications including in vitro diagnostics and therapeutic developments. More information can be found on their website.
Applied DNA Sciences (NASDAQ: APDN) has secured a safeCircle™ health services contract with a New York City investment firm for PCR-based COVID-19 testing. Starting in April 2022, the contract includes testing services for employees returning to in-person work. The safeCircle platform offers a comprehensive health testing solution, managing sample distribution, results reporting, and variant tracking. Mike Munzer from Applied DNA emphasized the importance of managing COVID-19 exposure as companies transition back to the office environment.
Applied DNA Sciences (NASDAQ: APDN) announced that CEO Dr. James A. Hayward will present at the 2022 Virtual Growth Conference hosted by Maxim Group LLC from March 28-30, 2022. The presentation will be available on-demand during the event. The conference will cover various sectors, including biotech and healthcare, and feature multiple presentations, discussions, and Q&A sessions. Applied DNA is known for its LinearDNA platform utilized in diagnostics and drug development. For more details, visit adnas.com.
Applied DNA Sciences (NASDAQ: APDN) and Spindle Biotech have signed a non-binding letter of intent to explore a collaboration on mRNA production. The partnership aims to utilize Applied DNA's LinearDNA™ platform to create chemically modified DNA templates for Spindle's advanced RNA polymerase. This integration is expected to enhance yield and simplify the production process, offering up to a ten-fold improvement in yield compared to traditional methods. The final agreement's execution depends on successful negotiations between the two parties.
Applied DNA Sciences (NASDAQ: APDN) announced a virtual fireside chat hosted by CEO Dr. James A. Hayward on March 14, 2022, during the 34th Annual Roth Investor Conference. The session will cover the company’s advancements in Polymerase Chain Reaction (PCR)-based DNA technologies. Key executives, including CFO Beth Jantzen and Clay Shorrock, will also conduct one-on-one investor meetings. Interested investors can request a meeting via email at oneononerequests@roth.com. Full details will be available on their website.
Applied DNA Sciences (NASDAQ: APDN) has successfully closed a registered direct offering of 1,496,400 shares of common stock at a price of $2.80 per share, yielding gross proceeds of approximately $4.2 million. Concurrently, the company issued unregistered warrants to purchase an equal number of shares. Following the offering, total outstanding shares will amount to 8,234,320. The net proceeds are intended for general corporate purposes, including advancing its LinearDNA manufacturing platform.
Applied DNA Sciences (NASDAQ: APDN) announced a registered direct offering of 1,496,400 shares at $2.80 per share, yielding gross proceeds of approximately $4.2 million. Alongside, the company will issue warrants to purchase the same number of shares at an exercise price of $2.84. The offering will close around February 24, 2022, subject to customary conditions. Proceeds will support general corporate purposes and advance the LinearDNA™ manufacturing platform.
Applied DNA Sciences (NASDAQ: APDN) announced the publication of a study demonstrating the efficacy of its LinearDNA vaccines in triggering strong immune responses and inhibiting tumor growth in preclinical mouse models. The research, published on bioRxiv, investigates vaccines targeting tumor-associated and tumor-specific antigens. The study highlighted the potential of LinearDNA in both human and veterinary cancer immunotherapy, with a projected market growth to $169 billion by 2028.
Applied DNA Sciences (APDN) reported a substantial revenue increase of 158% year-over-year, reaching $4.2 million for Q1 fiscal 2022, driven by high demand for COVID-19 testing amid the Omicron variant. Sequentially, revenue grew 37% from $3.0 million in Q4 2021. The company anticipates continued growth, with unaudited revenues of approximately $2.0 million in January 2022.
However, gross profit margin decreased to 27% due to higher costs in testing contracts. Net loss for the quarter was $4.7 million, or $0.63 per share.
